Catalent Inc. (CTLT): Price and Financial Metrics

Catalent Inc. (CTLT): $67.79

0.88 (+1.32%)

POWR Rating

Component Grades














  • Value is the dimension where CTLT ranks best; there it ranks ahead of 34.54% of US stocks.
  • The strongest trend for CTLT is in Growth, which has been heading down over the past 177 days.
  • CTLT's current lowest rank is in the Momentum metric (where it is better than 19.86% of US stocks).

CTLT Stock Summary

  • CTLT has a higher market value than 85.73% of US stocks; more precisely, its current market capitalization is $11,574,415,342.
  • The price/operating cash flow metric for CATALENT INC is higher than 87.62% of stocks in our set with a positive cash flow.
  • The volatility of CATALENT INC's share price is greater than that of 87.34% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to CATALENT INC, a group of peers worth examining would be RE, PKG, WSC, LDOS, and GTES.
  • CTLT's SEC filings can be seen here. And to visit CATALENT INC's official web site, go to

CTLT Valuation Summary

  • CTLT's price/earnings ratio is 28.3; this is 21.98% higher than that of the median Healthcare stock.
  • CTLT's price/sales ratio has moved up 1.1 over the prior 105 months.

Below are key valuation metrics over time for CTLT.

Stock Date P/S P/B P/E EV/EBIT
CTLT 2023-03-24 2.4 2.4 28.3 24.7
CTLT 2023-03-23 2.4 2.3 27.6 24.2
CTLT 2023-03-22 2.4 2.4 28.5 24.8
CTLT 2023-03-21 2.5 2.4 29.4 25.4
CTLT 2023-03-20 2.5 2.5 29.5 25.4
CTLT 2023-03-17 2.5 2.5 29.5 25.5

CTLT Growth Metrics

    Its year over year revenue growth rate is now at 25.17%.
  • Its 4 year net cashflow from operations growth rate is now at 52.44%.
  • Its 5 year net cashflow from operations growth rate is now at 52.44%.
Over the past 34 months, CTLT's revenue has gone up $1,884,600,000.

The table below shows CTLT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 4,757 329 409
2022-09-30 4,825 184 421
2022-06-30 4,828 439 503
2022-03-31 4,703.2 504.3 486.9
2021-12-31 4,483.5 441.3 563
2021-09-30 4,177.3 446.3 546.6

CTLT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTLT has a Quality Grade of C, ranking ahead of 31.5% of graded US stocks.
  • CTLT's asset turnover comes in at 0.461 -- ranking 93rd of 682 Pharmaceutical Products stocks.
  • INSM, SPPI, and HSKA are the stocks whose asset turnover ratios are most correlated with CTLT.

The table below shows CTLT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.461 0.342 0.125
2021-06-30 0.469 0.338 0.131
2021-03-31 0.459 0.332 0.129
2020-12-31 0.447 0.323 0.086
2020-09-30 0.451 0.322 0.082
2020-06-30 0.456 0.318 0.073

CTLT Stock Price Chart Interactive Chart >

Price chart for CTLT

CTLT Price/Volume Stats

Current price $67.79 52-week high $115.33
Prev. close $66.91 52-week low $40.69
Day low $67.17 Volume 9,389
Day high $68.08 Avg. volume 2,356,720
50-day MA $64.84 Dividend yield N/A
200-day MA $74.11 Market Cap 12.21B

Catalent Inc. (CTLT) Company Bio

Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologicsgene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue. (Source:Wikipedia)

CTLT Latest News Stream

Event/Time News Detail
Loading, please wait...

CTLT Latest Social Stream

Loading social stream, please wait...

View Full CTLT Social Stream

Latest CTLT News From Around the Web

Below are the latest news stories about CATALENT INC that investors may wish to consider to help them evaluate CTLT as an investment opportunity.

Catalent (CTLT) Declined on Lowered Guidance

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund posted a return of 6.92% net of fees compared to a 7.56% return for the S&P 500 Index. The fund’s underperformance in the quarter […]

Yahoo | March 29, 2023

Catalent (NYSE:CTLT) sheds 4.0% this week, as yearly returns fall more in line with earnings growth

Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...

Yahoo | March 27, 2023

2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch

According to the National Center for Advancing Translational Sciences, the average period from therapy discovery to Food and Drug Administration (FDA) approval is 14 years and costs $1 billion. Clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are growing because the increasing price of developing, testing, manufacturing, and marketing therapies has made it more important that pharmaceutical companies speed the process along with fewer failures. Rather than doing all the clinical trial work or manufacturing work in-house, more healthcare companies are turning to CROs and CDMOs to reduce overhead and expedite bringing therapies to market.

Yahoo | March 25, 2023

Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses

Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.

Yahoo | March 24, 2023

Should You Exit Catalent (CTLT)?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small/Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy outperformed the Russell 2500 Growth Index and returned 6.03% (gross), and the index return was 4.72%. For the full year, the strategy return […]

Yahoo | March 24, 2023

Read More 'CTLT' Stories Here

CTLT Price Returns

1-mo -0.63%
3-mo 50.61%
6-mo -6.32%
1-year -38.83%
3-year 34.37%
5-year 65.10%
YTD 50.61%
2022 -64.84%
2021 23.02%
2020 84.85%
2019 80.56%
2018 -24.10%

Continue Researching CTLT

Here are a few links from around the web to help you further your research on Catalent Inc's stock as an investment opportunity:

Catalent Inc (CTLT) Stock Price | Nasdaq
Catalent Inc (CTLT) Stock Quote, History and News - Yahoo Finance
Catalent Inc (CTLT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8773 seconds.